Pharmaceutical corporations by U.S. revenue 2018

In terms of revenue, Pfizer was the leading pharmaceutical company in the United States in 2018. The company generated 25.32 billion U.S. dollars from sales during the year, around two billion U.S. dollars more than its nearest competitor, Johnson and Johnson.

U.S. market is key for Pfizer

Pharmaceutical firm Pfizer has seen its revenue in the United States decline in recent years, but it still accounted for nearly 50 percent of the company’s overall revenue in 2019. Pfizer has generated consistent worldwide revenues of approximately 53 billion U.S. dollars since 2016. The majority of its revenue comes from the manufacture and sale of biopharmaceutical products. Prevnar 13 – a vaccine that helps protect against pneumococcal bacteria – was the best-selling product in the company’s range in 2019.

Pfizer’s business segments

In 2019, Pfizer reorganized its operating structure into three business segments: biopharma, Upjohn, and consumer healthcare. The biopharma business, which generates the largest share of the company’s revenue, is comprised of six key therapeutic areas, including vaccines, oncology, and internal medicine. Midway through 2019, Pfizer’s consumer healthcare business was combined with the respective business of GlaxoSmithKline (GSK), and the new joint venture began operating globally as GSK Consumer Healthcare.